Citigroup Raises TNDM Price Target, Maintains Neutral Rating: An Overview of Tandem Diabetes Care's Recent Analyst Actions

Citigroup has maintained a "Neutral" rating for Tandem Diabetes Care (TNDM) and raised its price target from $10.35 to $11.00 USD. The analyst action reflects ongoing evaluations by analysts as they respond to market conditions and company performance metrics for TNDM. The average target price for TNDM is $22.30, with a high estimate of $51.00 and a low estimate of $10.35, indicating a potential upside of 103.12% from the current price of $10.98.

Citigroup has maintained a "Neutral" rating for Tandem Diabetes Care (TNDM), while raising its price target from $10.35 to $11.00 USD. This adjustment reflects ongoing evaluations by analysts as they respond to market conditions and company performance metrics for TNDM.

The average target price for TNDM stands at $22.30, with a high estimate of $51.00 and a low estimate of $10.35. This indicates a potential upside of 103.12% from the current price of $10.98. The analyst action underscores the importance of continuous monitoring and assessment of market conditions and company performance.

According to MarketBeat, the consensus rating for TNDM is "Hold," with 15 analysts providing ratings over the past 12 months. This includes 1 sell rating, 8 hold ratings, and 6 buy ratings. The consensus price target is $32.71, with a high forecast of $59.00 and a low forecast of $14.00.

Analysts at various firms, such as Citigroup, Piper Sandler, and Wells Fargo, have been actively evaluating TNDM. Citigroup's latest update suggests a cautious approach, aligning with the broader consensus rating of "Hold." Investors are advised to closely monitor TNDM's performance and market conditions before making any investment decisions.

References:
[1] https://www.marketbeat.com/stocks/NASDAQ/TNDM/forecast/